Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navicixizumab - Mereo BioPharma/Feng Biosciences

Next Previous
Drug Profile

Navicixizumab - Mereo BioPharma/Feng Biosciences

Alternative Names: anti-DLL4/VEGF bispecific antibody - Mereo BioPharma/Feng Biosciences; OMP 305B83

Latest Information Update: 02 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Developer Feng Biosciences; OncoMed Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Stem cell modulators; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Jan 2023 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Jan 2023 No recent reports of development identified for phase-I development in Peritoneal-cancer(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top